Simulations Plus (NASDAQ:SLP) issued its earnings results on Sunday. The technology company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a return on equity of 24.44% and a net margin of 22.96%.
Simulations Plus stock traded down $8.28 during mid-day trading on Tuesday, hitting $71.05. The company had a trading volume of 23,687 shares, compared to its average volume of 287,831. Simulations Plus has a 12-month low of $26.00 and a 12-month high of $83.78. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 152.38, a P/E/G ratio of 7.63 and a beta of -0.17. The company’s fifty day moving average is $65.06 and its 200-day moving average is $65.43.
A number of equities research analysts recently commented on SLP shares. BidaskClub upgraded Simulations Plus from a “hold” rating to a “buy” rating in a research report on Wednesday, December 23rd. TheStreet upgraded Simulations Plus from a “c+” rating to a “b” rating in a research report on Friday. Taglich Brothers upgraded Simulations Plus from a “speculative buy” rating to a “buy” rating and set a $76.00 price objective on the stock in a research report on Wednesday, November 25th. Zacks Investment Research lowered Simulations Plus from a “hold” rating to a “sell” rating in a research report on Thursday, November 19th. Finally, Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Simulations Plus has an average rating of “Hold” and a consensus price target of $81.60.
In other news, Director Walter S. Woltosz sold 24,000 shares of the stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $68.95, for a total transaction of $1,654,800.00. Following the transaction, the director now owns 4,707,359 shares in the company, valued at approximately $324,572,403.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director David L. Ralph sold 5,000 shares of the stock in a transaction that occurred on Monday, November 30th. The shares were sold at an average price of $55.65, for a total value of $278,250.00. Following the transaction, the director now owns 16,581 shares in the company, valued at approximately $922,732.65. The disclosure for this sale can be found here. Insiders have sold a total of 64,881 shares of company stock worth $4,347,992 in the last quarter. Insiders own 31.57% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
See Also: Front-End Load
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.